NO993901L - Bisykliske aminosyrer - Google Patents

Bisykliske aminosyrer

Info

Publication number
NO993901L
NO993901L NO993901A NO993901A NO993901L NO 993901 L NO993901 L NO 993901L NO 993901 A NO993901 A NO 993901A NO 993901 A NO993901 A NO 993901A NO 993901 L NO993901 L NO 993901L
Authority
NO
Norway
Prior art keywords
amino acids
bicyclic amino
bicyclic
acids
amino
Prior art date
Application number
NO993901A
Other languages
English (en)
Other versions
NO993901D0 (no
NO313289B1 (no
Inventor
Beate Diefenbach
Simon Goodman
Joachim Morz
Peter Raddatz
Friedrich Rippmann
Matthias Wiesner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO993901D0 publication Critical patent/NO993901D0/no
Publication of NO993901L publication Critical patent/NO993901L/no
Publication of NO313289B1 publication Critical patent/NO313289B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993901A 1997-02-13 1999-08-12 Bisykliske aminosyrer, fremgangsmåte for fremstilling derav, farmasöytisk preparat, fremgangsmåte for fremstilling derav, samtanvendelse av forbindelsene til fremstilling av et legemiddel foranvendelse som <alfa>v-integrininhibitor NO313289B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19705450A DE19705450A1 (de) 1997-02-13 1997-02-13 Bicyclische aromatische Aminosäuren
PCT/EP1998/000636 WO1998035949A1 (de) 1997-02-13 1998-02-06 Bicyclische aromatische aminosäuren

Publications (3)

Publication Number Publication Date
NO993901D0 NO993901D0 (no) 1999-08-12
NO993901L true NO993901L (no) 1999-10-12
NO313289B1 NO313289B1 (no) 2002-09-09

Family

ID=7820093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993901A NO313289B1 (no) 1997-02-13 1999-08-12 Bisykliske aminosyrer, fremgangsmåte for fremstilling derav, farmasöytisk preparat, fremgangsmåte for fremstilling derav, samtanvendelse av forbindelsene til fremstilling av et legemiddel foranvendelse som <alfa>v-integrininhibitor

Country Status (25)

Country Link
EP (1) EP0964856B1 (no)
JP (1) JP4327257B2 (no)
KR (1) KR20000071030A (no)
CN (1) CN1085205C (no)
AR (1) AR010894A1 (no)
AT (1) ATE225776T1 (no)
AU (1) AU735313B2 (no)
BR (1) BR9807345A (no)
CA (1) CA2280727C (no)
CY (1) CY2341B1 (no)
CZ (1) CZ297366B6 (no)
DE (2) DE19705450A1 (no)
DK (1) DK0964856T3 (no)
ES (1) ES2183332T3 (no)
HU (1) HUP0001138A3 (no)
ID (1) ID22533A (no)
NO (1) NO313289B1 (no)
PL (1) PL335101A1 (no)
PT (1) PT964856E (no)
RU (1) RU2187506C2 (no)
SI (1) SI0964856T1 (no)
SK (1) SK284646B6 (no)
TR (1) TR199901962T2 (no)
WO (1) WO1998035949A1 (no)
ZA (1) ZA981178B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
TR200102944T2 (tr) 1999-04-13 2002-08-21 Basf Aktiengesellschaft İntegrin reseptör ligandları
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
WO2001047874A1 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
US6617461B2 (en) * 2000-01-25 2003-09-09 Kaneka Corporation Process for preparation of optically active N-substituted azetidine-2-carboxylic acids
CN100571772C (zh) * 2000-11-01 2009-12-23 默克专利有限公司 整联蛋白受体αvβ3和/或αvβ5的拮抗剂在制备用于治疗眼疾的药物中的用途
HUP0302718A3 (en) 2000-11-01 2011-03-28 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
CA2449054C (en) 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
PL207175B1 (pl) * 2001-08-01 2010-11-30 Merck Patent Gmbh Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
DE10305784A1 (de) * 2003-02-12 2004-08-26 Merck Patent Gmbh Verfahren zur Herstellug bicyclischer aromatischer Aminosäuren sowie deren Zwischenprodukte
DE10337863A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
ATE551060T1 (de) * 2004-06-04 2012-04-15 Scripps Research Inst Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2748251C (en) * 2008-12-26 2016-08-02 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
WO2011024987A1 (ja) * 2009-08-31 2011-03-03 塩野義製薬株式会社 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物
NZ628587A (en) 2012-03-06 2016-07-29 Boehringer Ingelheim Int Benzodioxanes in combination with other actives for inhibiting leukotriene production
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP6353899B2 (ja) 2013-07-15 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151690A1 (de) * 1981-12-29 1983-07-07 Hoechst Ag, 6230 Frankfurt "neue derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung"
FR2674854B1 (fr) * 1991-04-04 1995-03-03 Bouchara Nouvelles quinolones leur procede de preparation et les compositions pharmaceutiques en refermant.
JPH08504194A (ja) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
KR20000022190A (ko) * 1996-06-28 2000-04-25 플레믹 크리스티안 인테그린 저해제로서의 페닐알라닌 유도체
DE19654483A1 (de) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate

Also Published As

Publication number Publication date
CN1252064A (zh) 2000-05-03
DE19705450A1 (de) 1998-08-20
AU6620698A (en) 1998-09-08
ES2183332T3 (es) 2003-03-16
NO993901D0 (no) 1999-08-12
JP2001511789A (ja) 2001-08-14
EP0964856A1 (de) 1999-12-22
EP0964856B1 (de) 2002-10-09
CN1085205C (zh) 2002-05-22
PL335101A1 (en) 2000-04-10
HUP0001138A2 (hu) 2001-05-28
AR010894A1 (es) 2000-07-12
HUP0001138A3 (en) 2002-10-28
NO313289B1 (no) 2002-09-09
SK107199A3 (en) 2000-05-16
ID22533A (id) 1999-10-28
DK0964856T3 (da) 2003-02-10
CZ287599A3 (cs) 1999-11-17
CA2280727A1 (en) 1998-08-20
ZA981178B (en) 1999-05-21
CY2341B1 (en) 2004-02-06
CA2280727C (en) 2008-05-06
JP4327257B2 (ja) 2009-09-09
BR9807345A (pt) 2000-03-21
RU2187506C2 (ru) 2002-08-20
WO1998035949A1 (de) 1998-08-20
KR20000071030A (ko) 2000-11-25
TR199901962T2 (xx) 1999-12-21
AU735313B2 (en) 2001-07-05
ATE225776T1 (de) 2002-10-15
DE59805895D1 (de) 2002-11-14
PT964856E (pt) 2003-02-28
SI0964856T1 (en) 2003-04-30
CZ297366B6 (cs) 2006-11-15
SK284646B6 (sk) 2005-08-04

Similar Documents

Publication Publication Date Title
NO993901L (no) Bisykliske aminosyrer
DK0877018T3 (da) Sulfonylaminocarboxylsyrer
NO20002990L (no) Nytt overflateprotein
DE69839603D1 (de) Zierenden proteins
FI953837A0 (fi) Synteettisiä aktivoituvia aminohappoja
IS5375A (is) KAY-nýstárlegt ónæmisprótín
NO2010013I2 (no) Rekombinant FSH-CTP
DE69832623D1 (de) Mikrogefertigte kreisel
NO985680D0 (no) Peptidderivater
DE69815952D1 (de) Poliergerät
DE69830139D1 (de) Ultraschall lockenwickelgerät
NO994548D0 (no) Rekkverk
NO983849D0 (no) Peptidderivater
DE69816146D1 (de) Poliervorrichtung
BR9609671A (pt) Amino uracilas substituídas
DE69838161D1 (de) Poliervorrichtung
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69808762D1 (de) Verbindungsteil
DE69834398D1 (de) Anhänger
DE59806788D1 (de) Lauflichtanlage
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
ATA188297A (de) Beschlag
ATE204219T1 (de) Bondkopf
ITMI972543A0 (it) Proteina p27bbp

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees